AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:04 2024-04-29 am EDT 5-day change 1st Jan Change
12,024 GBX +0.30% Intraday chart for AstraZeneca PLC +6.88% +13.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Close Mixed in Monday Trading; Economic Sentiment Falls in April; Lawsuit Dents Deutsche Bank Shares MT
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement MT
ASTRAZENECA : JP Morgan maintains a Buy rating ZD
Deutsche Bank likes Frasers; Barclays cuts JD AN
AstraZeneca makes progress with Truqap and Enhertu cancer treatments AN
AstraZeneca: CHMP green light for Truqap + Faslodex CF
AstraZeneca: new positive data for Enhertu CF
FTSE 100 continues record run boosted by Anglo American, AstraZeneca RE
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study MT
AstraZeneca's Truqap Plus Faslodex Breast Cancer Treatment Bags EU Approval Recommendation MT
Hipgnosis Songs Fund backs new Blackstone bid AN
ASTRAZENECA : DZ Bank sticks Neutral ZD
ASTRAZENECA : UBS keeps a Sell rating ZD
ASTRAZENECA : Deutsche Bank remains Neutral ZD
ASTRAZENECA : Gets a Buy rating from Barclays ZD
Barclays Raises AstraZeneca PT, Affirms at Overweight MT
Peel Hunt cuts ConvaTec to 'reduce' AN
THE FTSE 100 is on a roll Our Logo
Health Care Drops Amid Mixed Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Drop in Afternoon Trading MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump MT
ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade Alphavalue
FTSE 100 shakes off red-hot US inflation gauge AN
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3 USD
Average target price
164.3 USD
Spread / Average Target
+10.02%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. Fitch Affirms AstraZeneca Rating on Stable Position in Pharmaceutical Sector